Identifying Potential Drug Targets and Biomarkers for PYY2 (G23615)

Target Name: PYY2

NCBI ID: G23615

PYY2

Other Name(s): peptide YY 2 (pseudogene) | Peptide YY 2 (pseudogene)

Identifying Potential Drug Targets and Biomarkers for PYY2

Pseudogenes, also known as pseudogenes or exogenous genes, are genes that are present in an organism but are not transcribed or translated into proteins. These genes can be generated by various mechanisms, including gene rearrangement and gene fusion ), and they often play a role in the development and progression of diseases. PYY2, a pseudogene located on chromosome 11q22, has recently been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

PYY2 function and localization

PYY2 is a 21-kDa protein that is expressed in various tissues and organs, including brain, pancreas, and muscle. It is highly conserved across different species, and its sequence is similar to that of other known pseudogenes, such as PYY1 and PYY3. PYY2 is predominantly localized to the cytoplasm of cells and is expressed in a variety of cell types, including epithelial, endothelial, and muscle cells.

Disease association

PYY2 has been implicated in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. PYY2 has been found to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. In neurodegenerative diseases, such as Alzheimer's disease, PYY2 has been shown to be overexpressed in the brain and to contribute to the progression of neurodegeneration. Additionally, PYY2 has been implicated in the development of autoimmune disorders, such as rheumatoid arthritis and type 1 diabetes.

Drug targeting

PYY2 has recently been identified as a potential drug target due to its unique structure and its expression in various tissues and organs. PYY2 has a single extracellular domain and a unique N-terminus that is rich in conserved secondary structure, such as a helix and a loop. This unique structure has been shown to interact with various signaling molecules and to play a role in the regulation of cellular processes, including cell adhesion, migration, and invasion.

PYY2 has also been shown to interact with several protein partners, including TGF-β1, FGF1, and PDGF. These interactions may play a role in the regulation of cellular processes that are important for disease progression, such as cell proliferation, angiogenesis, and inflammation . Additionally, PYY2 has been shown to be involved in the regulation of cellular processes that are important for the development and maintenance of tissues and organs, such as cell migration, migration of immune cells, and inflammation.

Biomarker potential

PYY2 has also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. PYY2 has been found to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, PYY2 has PYY2 has also been shown to be overexpressed in autoimmune disorders, such as rheumatoid arthritis and type 1 diabetes.

Conclusion

PYY2 is a pseudogene that has been shown to be involved in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and its expression in various tissues and organs make it a potential drug target or biomarker. Further research is needed to fully understand the role of PYY2 in disease progression and to develop effective treatments.

Protein Name: Peptide YY 2 (pseudogene)

The "PYY2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PYY2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets